Status:
UNKNOWN
Hyperinsulinemic Therapy in Sepsis
Lead Sponsor:
peter metrakos
Conditions:
Sepsis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Insulin regulates blood sugar and acts to suppress inflammation. Hyperinsulinemic Therapy is a protocol for Insulin administration that involves the administration of a calculated higher dose of insul...
Eligibility Criteria
Inclusion
- Admission to the ICU with a diagnosis of Septic shock or Severe Sepsis.
Exclusion
- Age less than 18 years old.
- Pregnancy.
- Patients who cannot provide informed consent and there is no surrogate decision maker.
- A delay of more than 24 hours between eligibility and randomization.
- Patients admitted to the intensive care unit for treatment of diabetic ketoacidosis or hyperosmolar state.
- Imminent death.
- Patients who the treating clinicians are not committed to full supportive care. This is confirmed by a documented treatment-limitation order that exceeds a "do-not-resuscitation" order.
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT01244178
Start Date
November 1 2010
Last Update
October 25 2013
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Victoria Hospital
Montreal, Quebec, Canada, H3A 1A1
2
Montreal General Hospital
Montreal, Quebec, Canada, H3G 1A4
3
King Khalid Univesity Hospital
Riyadh, Riyadh Region, Saudi Arabia, 11421